CL2023000090A1 - Coagonistas de los receptores de glp-1 y gip - Google Patents

Coagonistas de los receptores de glp-1 y gip

Info

Publication number
CL2023000090A1
CL2023000090A1 CL2023000090A CL2023000090A CL2023000090A1 CL 2023000090 A1 CL2023000090 A1 CL 2023000090A1 CL 2023000090 A CL2023000090 A CL 2023000090A CL 2023000090 A CL2023000090 A CL 2023000090A CL 2023000090 A1 CL2023000090 A1 CL 2023000090A1
Authority
CL
Chile
Prior art keywords
glp
gip receptor
coagonists
receptor coagonists
gip
Prior art date
Application number
CL2023000090A
Other languages
English (en)
Inventor
Patrick J Knerr
Brian Finan
Richard Dimarchi
Fa Liu
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of CL2023000090A1 publication Critical patent/CL2023000090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen coagonistas peptídicos de los receptores de GLP-1 y GIP humanos, los derivados de acción prolongada de los mismos y sus usos médicos en el tratamiento y/o la prevención de la obesidad, la diabetes y/o enfermedades hepáticas.
CL2023000090A 2020-07-22 2023-01-09 Coagonistas de los receptores de glp-1 y gip CL2023000090A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063055063P 2020-07-22 2020-07-22
EP20192415 2020-08-24

Publications (1)

Publication Number Publication Date
CL2023000090A1 true CL2023000090A1 (es) 2023-07-07

Family

ID=77179984

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000090A CL2023000090A1 (es) 2020-07-22 2023-01-09 Coagonistas de los receptores de glp-1 y gip

Country Status (14)

Country Link
US (1) US20230346961A1 (es)
EP (1) EP4185606A1 (es)
JP (1) JP2023534130A (es)
KR (1) KR20230042019A (es)
CN (1) CN116157414A (es)
AU (1) AU2021313377A1 (es)
BR (1) BR112023000229A2 (es)
CA (1) CA3184723A1 (es)
CL (1) CL2023000090A1 (es)
CO (1) CO2023000125A2 (es)
IL (1) IL299707A (es)
MX (1) MX2023000403A (es)
TW (1) TW202214679A (es)
WO (1) WO2022018185A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117402219B (zh) * 2022-07-13 2024-07-30 杭州中美华东制药有限公司 Glp-1/gip双激动剂及其制备方法和用途
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CL2009001425A1 (es) 2008-06-17 2010-04-30 Univ Indiana Res & Tech Corp Analogos de glucagon con un aminoacido aromatico grande que carece de cadena lateral de imidazol que le confiere actividad agonista del receptor gip; composiciones farmaceutica; kit que los contiene y uso para reducir el aumento de peso, tratar la diabetes o inducir paralisis del tracto intestinal.
AR084558A1 (es) * 2010-12-22 2013-05-22 Marcadia Biotech Metodos para tratar trastornos metabolicos y obesidad con peptidos basados en glucagon activos para el receptor de peptido insulinotropico dependiente de glucosa (gip)/peptido-1 similar al glucagon (glp-1)
KR102002783B1 (ko) 2011-06-10 2019-07-24 베이징 한미 파마슈티컬 컴퍼니 리미티드 포도당 의존성 인슐리노트로핀 폴리펩타이드 유사물질, 이의 약학적 조성물 및 응용
EP4331667A3 (en) * 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
EP2844669B1 (en) 2012-05-03 2018-08-01 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CA2910903A1 (en) * 2013-05-02 2014-11-06 Novo Nordisk A/S Oral dosing of glp-1 compounds
PE20151770A1 (es) 2013-05-28 2015-12-11 Takeda Pharmaceutical Compuesto peptidico
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
AU2014345569B2 (en) * 2013-11-06 2020-08-13 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
JOP20200119A1 (ar) 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
EP3827015A1 (en) 2018-07-23 2021-06-02 Eli Lilly and Company Gip/glp1 co-agonist compounds

Also Published As

Publication number Publication date
TW202214679A (zh) 2022-04-16
CA3184723A1 (en) 2022-01-27
CN116157414A (zh) 2023-05-23
BR112023000229A2 (pt) 2023-01-31
AU2021313377A1 (en) 2023-02-02
IL299707A (en) 2023-03-01
EP4185606A1 (en) 2023-05-31
US20230346961A1 (en) 2023-11-02
CO2023000125A2 (es) 2023-04-17
KR20230042019A (ko) 2023-03-27
JP2023534130A (ja) 2023-08-08
WO2022018185A1 (en) 2022-01-27
MX2023000403A (es) 2023-02-02

Similar Documents

Publication Publication Date Title
CL2023000090A1 (es) Coagonistas de los receptores de glp-1 y gip
CL2023000087A1 (es) Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral
CL2020002796A1 (es) Derivados de gip y usos de estos
BR112022000027A2 (pt) Compostos agonistas gipr
PE20170087A1 (es) Composicion para tratar la diabetes mellitus, que comprende insulina y un agonista doble de glp-1/glucagon
CO2019014028A2 (es) Posologías para la administración de análogos de péptido de tipo glucagon-2 (glp-2)
UY29020A1 (es) Saliciltiazoles sustituidos con difenilamina o derivados de difenilamina, procedimientos para su preparacinn y su uso.-
CO6280470A2 (es) Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina
HN2003000217A (es) Agonistas del receptor (vpac2) del peptido activamente de la adenilato ciclasa hipofisiaria (pacap) y sus metodos de uso farmacologico.
UY28277A1 (es) Ligandos del receptor cannabioides y usos de los mismos
UY29244A1 (es) Combinaciones medicas
ECSP21030933A (es) Análogos de proteína tirosina-tirosina y métodos de uso de esta
AR106364A1 (es) Derivados de insulina y sus usos médicos
EA202091533A1 (ru) Способы лечения диабета, гепатита и/или воспалительного заболевания печени
PE20221518A1 (es) Analogos de incretina y sus usos
CO2023008676A2 (es) Compuestos polipéptidos modificados con lactama
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
ECSP22019177A (es) Proteínas de fusión nkg2d y sus usos
AR123039A1 (es) Coagonistas de los receptores de glp-1 y gip
CO2023009085A2 (es) Pauta posológica de levodopa
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
CL2022000894A1 (es) Moduladores atf6 y sus usos.
ECSP066280A (es) Antranilamidopiridonas que inhiben vegfr-2 y vegfr-3
MX9306494A (es) Polipeptidos ó - sustituidos que tienen actividad terapeutica.